Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 tumor-infiltrating lymphocyte therapy vs chemotherapy in advanced melanoma
ChiCTR2600118298Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LM103 in melanoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: IRC-assessed progression-free survival (PFS). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
LM103
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2600118298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118298.